Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Discussing adjuvant cancer therapyN Leighl, M Gattellari, P Butow, et al.
Current Oncology (Toronto, Ont.)|December 31, 2015
Pilot of three objective markers of physical health and chemotherapy toxicity in older adultsT Hsu, R Chen, S C X Lin, et al.
Cancer Treatment Reviews|March 24, 2018
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLCB Melosky, Q Chu, R A Juergens, et al.
European Journal of Cancer (Oxford, England : 1990)|December 19, 2008
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials GroupGlenwood Goss, Frances A Shepherd, Scott Laurie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trialJ McDonald, N Swami, B Hannon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancerB Besse, N Leighl, J Bennouna, et al.
Current Oncology (Toronto, Ont.)|November 12, 2019
The generation of two specific cancer costing algorithms using Ontario administrative databasesN Mittmann, S Y Cheng, N Liu, et al.
Current Oncology (Toronto, Ont.)|March 12, 2019
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancerS A Laurie, S Banerji, N Blais, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohortY Li, M Wong, L Zhan, et al.
Pageof 2